Effect of Concomitant Use of Polaprezinc and Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients
2.2. H. pylori Diagnosis
2.3. Esophagogastroduodenoscopy
2.4. H. pylori Eradication Therapy
2.5. Statistical Analysis
2.6. Ethical Considerations
3. Results
3.1. Patient Characteristics
3.2. Eradication Rates in the VAC and VACP Groups
3.3. Eradication Rates in the Severe Atrophic Gastritis Group
3.4. Effect of Age on Eradication Rate in the Atrophic Gastritis Group
3.5. Adverse Events
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Lee, Y.C.; Chiang, T.H.; Chou, C.K.; Tu, Y.K.; Liao, W.C.; Wu, M.S.; Graham, D.Y. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology 2016, 150, 1113–1124.e5. [Google Scholar] [CrossRef] [PubMed]
- Yan, L.; Chen, Y.; Chen, F.; Tao, T.; Hu, Z.; Wang, J.; You, J.; Wong, B.C.; Chen, J.; Ye, W. Effect of Helicobacter pylori Eradication on Gastric Cancer Prevention: Updated Report From a Randomized Controlled Trial With 26.5 Years of Follow-up. Gastroenterology 2022, 163, 154–162.e3. [Google Scholar] [CrossRef] [PubMed]
- Fukase, K.; Kato, M.; Kikuchi, S.; Inoue, K.; Uemura, N.; Okamoto, S.; Terao, S.; Amagai, K.; Hayashi, S.; Asaka, M. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open-label, randomised controlled trial. Lancet 2008, 372, 392–397. [Google Scholar] [CrossRef] [PubMed]
- Okamura, T.; Suga, T.; Nagaya, T.; Arakura, N.; Matsumoto, T.; Nakayama, Y.; Tanaka, E. Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: A multi-generational comparison. Helicobacter 2014, 19, 214–220. [Google Scholar] [CrossRef] [PubMed]
- Schubert, J.P.; Warner, M.S.; Rayner, C.K.; Roberts-Thomson, I.C.; Mangoni, A.A.; Costello, S.; Bryant, R.V. Increasing Helicobacter pylori clarithromycin resistance in Australia over 20 years. Intern. Med. J. 2021, 52, 1554–1560. [Google Scholar] [CrossRef]
- Ho, J.J.; Navarro, M.; Sawyer, K.; Elfanagely, Y.; Moss, S.F. Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis. Am. J. Gastroenterol. 2022, 117, 1221–1230. [Google Scholar] [CrossRef] [PubMed]
- Graham, D.Y.; Lee, S.Y. How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly. Gastroenterol. Clin. North Am. 2015, 44, 537–563. [Google Scholar] [CrossRef] [PubMed]
- Gisbert, J.P.; Calvet, X. Review article: Non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment. Pharmacol. Ther. 2011, 34, 604–617. [Google Scholar] [CrossRef] [PubMed]
- Gatta, L.; Vakil, N.; Vaira, D.; Scarpignato, C. Global eradication rates for Helicobacter pylori infection: Systematic review and meta-analysis of sequential therapy. BMJ 2013, 347, f4587. [Google Scholar] [CrossRef] [PubMed]
- Furuta, T.; Shirai, N.; Takashima, M.; Xiao, F.; Hanai, H.; Sugimura, H.; Ohashi, K.; Ishizaki, T.; Kaneko, E. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther. 2001, 69, 158–168. [Google Scholar] [CrossRef]
- Suzuki, S.; Gotoda, T.; Kusano, C.; Ikehara, H.; Ichijima, R.; Ohyauchi, M.; Ito, H.; Kawamura, M.; Ogata, Y.; Ohtaka, M.; et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: A multicentre randomised trial in Japan. Gut 2020, 69, 1019–1026. [Google Scholar] [CrossRef]
- Sakurai, Y.; Nishimura, A.; Kennedy, G.; Hibberd, M.; Jenkins, R.; Okamoto, H.; Yoneyama, T.; Jenkins, H.; Ashida, K.; Irie, S.; et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects. Clin. Transl. Gastroenterol. 2015, 6, e94. [Google Scholar] [CrossRef] [PubMed]
- Jenkins, H.; Sakurai, Y.; Nishimura, A.; Okamoto, H.; Hibberd, M.; Jenkins, R.; Yoneyama, T.; Ashida, K.; Ogama, Y.; Warrington, S. Randomised clinical trial: Safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment. Pharmacol. Ther. 2015, 41, 636–648. [Google Scholar] [CrossRef] [PubMed]
- Murakami, K.; Sakurai, Y.; Shiino, M.; Funao, N.; Nishimura, A.; Asaka, M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: A phase III, randomised, double-blind study. Gut 2016, 65, 1439–1446. [Google Scholar] [CrossRef] [PubMed]
- Kakiuchi, T.; Okuda, M.; Matsuo, M.; Fujimoto, K. Smart Gene as an effective non-invasive point-of-care test to detect Helicobacter pylori clarithromycin-resistant mutation. J. Gastroenterol. Hepatol. 2022, 37, 1719–1725. [Google Scholar] [CrossRef] [PubMed]
- Chey, W.D.; Mégraud, F.; Laine, L.; López, L.J.; Hunt, B.J.; Howden, C.W. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology 2022, 163, 608–619. [Google Scholar] [CrossRef] [PubMed]
- Ito, M.; Shii, D.; Segami, T.; Kojima, R.; Suzuki, Y. Preventive actions of N-(3-aminopropionyl)-L-histidinato zinc (Z-103) through increases in the activities of oxygen-derived free radical scavenging enzymes in the gastric mucosa on ethanol-induced gastric mucosal damage in rats. JPN J. Pharmacol. 1992, 59, 267–274. [Google Scholar] [CrossRef] [PubMed]
- Hiraishi, H.; Oinuma, T.; Sasai, T.; Yamaguchi, N.; Shimada, T.; Terano, A. Polaprezinc protects gastric mucosal cells from noxious agents through anti-oxidant properties in vitro. Gastroenterology 1998, 114, A149. [Google Scholar] [CrossRef]
- Ueda, K.; Ueyama, T.; Oka, M.; Ito, T.; Tsuruo, Y.; Ichinose, M. Polaprezinc (Zinc L-Carnosine) Is a Potent Inducer of Anti-oxidative Stress Enzyme, Heme Oxygenase (HO)-1—A New Mechanism of Gastric Mucosal Protection. J. Pharmacol. Sci. 2009, 110, 285–294. [Google Scholar] [CrossRef] [PubMed]
- Kuwayama, H. Zinc compound is a novel, highly effective triple therapy for eradication of Helicobacter pylori. Gastroenterology 1995, 108, A139, (Abstract). [Google Scholar]
- Kashimura, H.; Suzuki, K.; Hassan, M.; Ikezawa, K.; Sawahata, T.; Watanabe, T.; Nakahara, A.; Mutoh, H.; Tanaka, N. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 1999, 13, 483–487. [Google Scholar] [CrossRef] [PubMed]
- Mahmoud, A.; Abuelazm, M.; Ahmed, A.A.S.; Abdalshafy, H.; Abdelazeem, B.; Brašić, J.R. Efficacy and Safety of Polaprezinc-Based Therapy versus the Standard Triple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2022, 14, 4126. [Google Scholar] [CrossRef] [PubMed]
- Kimura, K.; Takemoto, T. An Endoscopic Recognition of the Atrophic Border and its Significance in Chronic Gastritis. Endoscopy 1969, 1, 87–97. [Google Scholar] [CrossRef]
- Malfertheiner, P.; Mégraud, F.; O’Morain, C.A.; Gisbert, J.P.; Kuipers, E.J.; Axon, A.T.; Bazzoli, F.; Gasbarrini, A.; Atherton, J.; Graham, D.Y.; et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017, 66, 6–30. [Google Scholar] [CrossRef] [PubMed]
- Suzuki, H.; Mori, H. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J. Gastroenterol. 2017, 53, 354–361. [Google Scholar] [CrossRef] [PubMed]
- Mori, H.; Suzuki, H.; Omata, F.; Masaoka, T.; Asaoka, D.; Kawakami, K.; Mizuno, S.; Kurihara, N.; Nagahara, A.; Sakaki, N.; et al. Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: A multicenter study with a large number of patients. Ther. Adv. Gastroenterol. 2019, 12, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Suzuki, S.; Gotoda, T.; Kusano, C.; Iwatsuka, K.; Moriyama, M. The Efficacy and Tolerability of a Triple Therapy Containing a Potassi-um-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. Am. J. Gastroenterol. 2016, 111, 949–956. [Google Scholar] [CrossRef] [PubMed]
- Shichijo, S.; Hirata, Y.; Niikura, R.; Hayakawa, Y.; Yamada, A.; Mochizuki, S.; Matsuo, K.; Isomura, Y.; Seto, M.; Suzuki, N.; et al. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice. J. Dig. Dis. 2016, 17, 670–675. [Google Scholar] [CrossRef] [PubMed]
- Noda, H.; Noguchi, S.; Yoshimine, T.; Goji, S.; Adachi, K.; Tamura, Y.; Izawa, S.; Ebi, M.; Yamamoto, S.; Ogasawara, N.; et al. A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori. J. Gastrointestin. Liver Dis. 2016, 25, 283–288. [Google Scholar] [CrossRef] [PubMed]
- PubChem. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/Promac#section=Structures (accessed on 18 December 2023).
- Shen, W.; Zhao, X.; Han, Z.; Miao, Y.; Huang, H.; Zhang, Z.; Dong, L.; Nie, Y.; Li, H.; Ni, R. Efficacy and safety of polaprezinc in the treatment of gastric ulcer: A multicenter, randomized, double-blind, double-dummy, positive-controlled clinical trial. Med. Eng. Phys. 2022, 110, 103860. [Google Scholar] [CrossRef] [PubMed]
- Sunairi, M.; Watanabe, K.; Suzuki, T.; Tanaka, N.; Kuwayama, H.; Nakajima, M. Effects of anti-ulcer agents on antibiotic activity against Helicobacter pylori. Eur. J. Gastroenterol. Hepatol. 1994, 6 (Suppl. 1), S121–S124. [Google Scholar] [PubMed]
- Kalkan, I.H.; Sapmaz, F.; Güliter, S.; Atasoy, P. Severe gastritis decreases success rate of Helicobacter pylori eradication. Wien. Klin. Wochenschr. 2015, 128, 329–334. [Google Scholar] [CrossRef] [PubMed]
- Sipponen, P.; Kekki, M.; Seppala, K.; Siurala, M. The relationships between chronic gastritis and gastric acid secretion. Aliment. Pharmacol. Ther. 1996, 10 (Suppl. 1), 103–118. [Google Scholar] [CrossRef] [PubMed]
- Taniguchi, Y.; Kimura, K.; Yoshida, Y.; Seki, M.; Kumakura, Y.; Satoh, K.; Kihira, K.; Ido, K.; Mato, M. Age-related changes in the microvessels of the human stomach: An ultra-structural study. J. Clin. Gastroenterol. 1993, 17 (Suppl. 1), S92–S98. [Google Scholar] [CrossRef] [PubMed]
- Kusunoki, M.; Yuki, M.; Ishitobi, H.; Kobayashi, Y.; Nagaoka, M.; Takahashi, Y.; Fukuba, N.; Komazawa, Y.; Shizuku, T.; Kinoshita, Y. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication. Intern. Med. 2019, 58, 1549–1555. [Google Scholar] [CrossRef]
VAC | VACP | p-Value | |
---|---|---|---|
Number | 165 | 36 | |
Mean age ± CI (years) | 65.7 ± 14.5 | 62.4 ± 14.2 | 0.22 |
Male–female | 103:62 | 20:16 | 0.46 |
<60 Years | ≥60 Years | p-Value | |
---|---|---|---|
VAC %(n/N) | 89.8 (19/22) | 83.8 (62/74) | 0.793 |
95% CI | 66.7–95.2 | 73.8–90.5 | |
VACP %(n/N) | 100 (5/5) | 100 (20/20) | – |
95% CI | 56.6–100 | 83.9–100 |
VAC | VACP | p-Value | |
---|---|---|---|
Skin eruption | 3 | 0 | |
Diarrhea | 5 | 1 | |
Nausea | 2 | 3 | |
Total | 10 | 4 | 0.283 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Suzuki, Y.; Katayama, Y.; Fujimoto, Y.; Toyoda, K.; Takahashi, M.; Tamano, M. Effect of Concomitant Use of Polaprezinc and Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication. Gastroenterol. Insights 2024, 15, 386-395. https://doi.org/10.3390/gastroent15020027
Suzuki Y, Katayama Y, Fujimoto Y, Toyoda K, Takahashi M, Tamano M. Effect of Concomitant Use of Polaprezinc and Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication. Gastroenterology Insights. 2024; 15(2):386-395. https://doi.org/10.3390/gastroent15020027
Chicago/Turabian StyleSuzuki, Yuto, Yasumi Katayama, Yo Fujimoto, Koji Toyoda, Morio Takahashi, and Masaya Tamano. 2024. "Effect of Concomitant Use of Polaprezinc and Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication" Gastroenterology Insights 15, no. 2: 386-395. https://doi.org/10.3390/gastroent15020027